• Green Thumb Industries is a cannabis cultivator, processor, and dispensary operator, with a growing base of operations nationwide that is founded on a vision of forming deep connections to the communities the company’s dispensaries serve
• Green Thumb is headquartered in Chicago and recently announced its 65th store, which will be its third retail outlet in New Jersey
• The company now operates in 14 states with 14 cannabis cultivation and manufacturing facilities
• Green Thumb’s Q2 filing reported an 85.4 percent YOY increase in revenues and its sixth consecutive quarter of positive cash flow from operations

Cannabis cultivator and retailer Green Thumb Industries (CSE: GTII) (OTCQX: GTBIF), a company with a well-rounded suite of nationally branded products designed for safe, responsible adult use, is aggressively expanding its footprint. The company’s Q2 filing in August reported that revenues had risen 85.4 percent YOY to $221.9 million, a sequential increase of 14.1 percent, with its sixth consecutive quarter of positive cash flow from operations. Adjusted Operating EBITDA grew 11.1 percent sequentially and more than doubled from the same period last year to $79.3 million (https://ibn.fm/sZUbj). InvestorBrandNetwork (“IBN”) spoke with Green Thumb Board of Directors member Wendy Berger, who noted that Green Thumb recently announced its 65th retail location — its third in the state of New Jersey — and that the company currently has operations in 14 states, with 14 cultivation and manufacturing facilities. “Everybody knows it is still very difficult to raise money in this business, even for companies like Green Thumb. And without institutional investors, you really have to work harder to identify investors,” Berger told IBN. “We think we have done a great job of speaking a language that investors really can understand and telling the story of Green Thumb in a way that is financially responsible.” The company’s dispensaries operate under the trademarked brand Rise, distributing a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rhythm, and The Feel Collection. Green Thumb holds more than 30 additional licenses for future retail locations across its markets as it begins to seek out a larger clientele. “In the very early days, our strategy was, contrary to many of our competitors, we chose secondary and tertiary markets, and the advantage there was to be the only one,” Berger said. “In places like Erie, Pennsylvania, (we) left people scratching their heads saying, ‘Why wouldn’t they go to Philadelphia first?’ And when we looked around at Erie, we were the only dispensary within a 70-mile radius. We have always been a company that prides ourselves on being a part of a community and being deeply connected and involved in the community and that’s much easier to do and we can be more impactful when we are in smaller communities.” Green Thumb is now headquartered in Chicago, but began in a much smaller location about 30 miles to the northwest. “Our very first store ever was in a town called Mundelein, Illinois. Which I am guessing you have never heard of,” Berger told IBN. “It is one of the top performing stores in all of Illinois, and it is not in downtown Chicago. We have an incredibly loyal customer base. We are deeply entrenched in the community, and people keep coming back.” On October 16, Green Thumb hosted a grand reopening of its Rise Mundelein store, with the town’s mayor in attendance, celebrating the store’s expansion after six years in business. “Rise Mundelein has been an important part of the Green Thumb story since opening as Illinois’ first medical dispensary in 2015. On January 1, 2020, we were one of the first stores in the state to serve adult-use consumers,” Green Thumb Founder and CEO Ben Kovler stated in a news release about the event (https://ibn.fm/Jhk0H). “Americans are overwhelmingly choosing cannabis for well-being and we look forward to enhancing our patient and customer experience at Rise Mundelein for today and the future.” And Green Thumb is embracing the opportunity to provide education on the benefits of cannabis as the plant’s stigma begins to fade in society. “We want to be on the corner of Main and Main. We want to be more (of what) Starbucks wants to be,” Berger said. “I think that there is still often a sort of this dismissal that we (in the cannabis industry) are not sophisticated operators when in fact we really are, and the proof of that is that we are drawing people from other industries into this business who bring with them their expertise.” For more information, visit the company’s website at www.GTIGrows.com.

• Cannabis flower and derivatives producer Flora Growth Corp. is an established brand builder with a seed-to-supply pipeline of cannabis CPG products from Colombia to North America to Europe and many other destinations around the world
• Flora Growth’s commitment to its premium and mindful consumer packaged goods brand and product portfolio is now being enhanced with the company’s announcement it has opened a pharmaceutical division
• Flora Pharma will concentrate on identifying opportunities for novel treatments in specific medical conditions, using a cost-effective process for establishing drug product safety and efficacy, honoring FDA and NHS regulatory standards

Internationally focused cannabis cultivator and brand builder Flora Growth (NASDAQ: FLGC) has been establishing strategic partnerships, commercial relationships, and infrastructure as part of the company’s growing distribution channels and markets for its premium cannabis consumer packaged goods (“CPG”) products, and on Oct. 6 announced the next stage in its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma will spearhead Flora Growth’s efforts to run clinical trials and develop therapies for specific disease states and conditions by identifying opportunities within the cannabis industry where “scientific gaps” have yet to respond to those conditions. In tandem with a team of artificial intelligence and machine learning experts, the group will develop a proprietary drug development platform to identify bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions, and then launch cost-effective studies in collaboration with academic institutions to comply with the traditional pharmaceutical regulatory route to proving safety and efficacy. The Oct. 6 news release noted that Flora Growth has signed an agreement to begin scientific clinical trials on the use of cannabinoids to treat fibromyalgia and chronic pain, with the primary research sites for the global effort located in the United States and the United Kingdom (https://ibn.fm/wnC6O). The announcement also noted that Flora Pharma expects to fast-track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.), and specified that the Human Pilot Study will be run in coordination with an internationally recognized clinical research group based at the University of Manchester. “Our team is incredibly excited to announce our entry into cannabinoid science,” President and CEO Luis Merchan stated. “Since our inception, the Flora team has successfully navigated significant barriers to enable the development, manufacturing, and commercialization of cannabis products in Colombia. Commercial harvests are well underway and it is now that we’re able to turn our attention to what we believe is the long-term future of our industry and to hedge ourselves further against the commoditization of raw cannabis materials.” The company’s aim is to create novel downstream prescription cannabinoid-based medicines as well as nutraceutical cannabis products, thereby diversifying Flora Growth’s revenue streams while using high margins and low debt to create sustainable, long-term growth. The company recently announced that it achieved $2.1 million in revenues for the first half of the year through June 30 (https://ibn.fm/71QUR). Flora Growth has developed its cultivation and processing infrastructure in the favorable Colombian market, including a vertically integrated footprint in a region known for its high-quality agricultural goods, an incredibly skilled labor force, and their team’s innate ability to produce premium cannabis with what the company believes is the lowest cost in the global market at $0.06/gram and 60% lower than its nearest Colombian peer. In July, President Ivan Duque solidified the country’s drive toward international cannabis trade by progressing from medicated oil and extract exports to fully lifting a ban on cannabis exports for cannabis used in food, beverage, cosmetics, and textiles markets, as well as pharmaceuticals (https://ibn.fm/Py6d9). With an expanding international distribution pipeline and more governments around the world wanting to regulate and participate in the global cannabis market, Flora has plans for its products to find their way all around the world. As a result of Colombia’s northern neighbor Panama recently passing legislation legalizing medical cannabis (https://ibn.fm/8JGxv), Flora most recently announced that it executed an agreement with Panamanian importer and distributor Robust Farms Inc. to supply its premium cannabidiol (“CBD”)-derivative products (https://ibn.fm/30azl). “While Flora is focused on its cannabis cultivation and processing operations in Colombia, as well as utilizing those raw materials throughout its premium and mindful global cannabis consumer packaged goods brand and product portfolio, the management team and board of directors has acknowledged and is committed to moving ahead with applied research initiatives in medical cannabis, forming Flora Pharma, in order to become a leader in the discovery, development, manufacturing, and commercialization of novel, phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of diseases,” the Oct. 6 news release states. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The 2018 U.S. Farm Bill removed “hemp” from the definition of cannabis but did not allow for inclusion of cannabidiol (“CBD”) in food or supplements
• Regulations will remain in terms of labeling and serving size, and they will be determined by CDPH (California Department of Public Health)
• Green Hygienics exclusively works with industrial hemp and stands to benefit from the signing of AB45 in California

The Farm Bill of 2018 was a game-changer in the hemp industry. Signed into law in December 2018, the Farm Bill removed “hemp” (Cannabis sativa L) and its derivatives comprised of a low concentration (less than 0.3%) of the psychoactive 9-tetrahydrocannabinol (“THC”) compound from the Controlled Substances Act definition of cannabis. Within the bill, the FDA preserved authoritative rights over hemp products (https://ibn.fm/5Zy7w). Therefore, all hemp products must meet any applicable FDA requirements or standards – much like any other product sold legally on the market. Assembly Bill 45 and Its Provisions Recently, more than three years after this ruling, Assembly Bill 45 (AB45) was signed by Governor Gavin Newsome, allowing for hemp-derived cannabinoids, extracts, and derivatives, in food and dietary supplements. However, AB45 does not come without restrictions (https://ibn.fm/wQL1d). The legislation comes only weeks after the FDA denied two New Dietary Ingredient applications filed by well-known CBD brands. There is currently no guidance for the serving size, which CDPH will address. Key provisions of the bill include:

• The food, drink, supplement, etc., is not adulterated by including industrial hemp or its derived cannabinoids, derivatives, or extracts. Manufacturers must register with theCDPH, demonstrate the proper industrial hemp sourcing, and comply with good manufacturing practices. Industrial hemp may not be included in any product that contains alcohol, tobacco, or nicotine.
• The use of any cannabinoid known to exhibit intoxicating properties is prohibited. For example, under AB45, THC – including delta 9 and delta 8 derivatives – is strictly prohibited. The CDPH will have full discretion to include or exclude within the definition of any other cannabinoid (except CBD) that has been determined to cause intoxication.
• AB45 only focuses on the final extract, which cannot exceed 0.3% THC concentration – not acknowledging the Interim Final Rule of the Drug Enforcement Administration (“DEA”) to classify any hemp extraction that exceeds the 0.3% rule as a Schedule 1 controlled substance.
• Inhalable products within the state lines are prohibited until the new tax on inhalable products is authorized.
• Hemp manufacturers must undergo rigorous testing requirements – including that the hemp must be tested by an independent third-party testing laboratory in raw extract final form. Testing requirements for contamination levels will be the same as the ones used for cannabis.
• AB45 prohibits labeling, advertising, and marketing any hemp product using a “health-related statement.” The packaging and labeling must include:
• A label, barcode, and an internet website or QR code that links to the certificate of analysis containing the product name, contact information, batch number, the concentration of cannabinoids, and the contaminant levels
• An expiration or “best by” date, if applicable
• A statement that indicates the product should be avoided by children, pregnant, or breastfeeding mothers unless discussed with a medical professional
• A statement that all cannabinoid products should be kept out of the reach of children
• The statement: THE FDA HAS NOT EVALUATED THIS PRODUCT FOR SAFETY OR EFFICACY

Companies that only grow and produce industrial hemp stand to benefit from Governor Newsome signing AB45. With a focus on the high standard cultivation and processing of industrial hemp, California-based Green Hygienics Holdings (OTCQB: GRYN) is one company expected to benefit from the new bill. The company grows its hemp in a controlled environment at its farm in California, which, with 824 acres and 392,000 square feet of greenhouse space, is the largest USDA Certified Organic hemp for CBD farm in North America. The company will soon manufacture pharmaceutical-grade bioactive cannabinoids and other active ingredients that can be used for multiple applications in various sectors such as the pharmaceutical, nutraceutical and skincare industries. Green Hygienics is registered with the FDA and was granted USDA Organic Certification in 2020. Products available from the company are currently found in the US, and will be in international markets soon. For more information, visit the company’s website at www.GreenHygienics.com. NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

In Tuesday morning trading, the ProShares Bitcoin Strategy ETF (NYSE: BITO) made its debut, marking a monumental occasion in the developing story of cryptocurrency regulation. The fund, which tracks CME bitcoin futures, or contracts speculating on the future prices of bitcoin, rose by roughly 3% early in the session and continues to hold those gains at time of publishing. The crypto sector as a whole has pursued a bitcoin-focused ETF for years now, with asset managers submitting proposals for spot bitcoin ETFs as early as 2017. To date, however, the U.S. Securities and Exchange Commission had consistently rejected these proposals, maintaining the stance that none of the applications were able to prove market resistance to manipulation. While the ProShares Bitcoin Strategy ETF falls short of the spot bitcoin ETF that many in the industry hope is on the horizon, experts agree that Tuesday’s opening stands as a turning point in the regulatory approach of the SEC. “Remember, there’s a difference between the cash ETF, obviously, and the ETF that everybody’s talking about right now. I have a preference for the cash ETF, but I love the fact that the SEC is allowing for the futures ETF,” Anthony Scaramucci, founder and managing partner of SkyBridge Capital, told CryptoCurrencyWire in an exclusive. “It’s just a sign that they’ve decided that they know the blockchain is going to be a very big component of the future of the financial services industry. I take this as a monumental decision…to allow the United States to stay the leader in financial services globally. I think it’s a very positive sign.” To stay up to date on the latest cryptocurrency news, signup for the CryptoCurrencyWire newsletter at www.CryptoCurrencyWire.com and for more on SkyBridge Capital & First Trust Skybridge Bitcoin Fund L.P. visit www.SkyBridgeBitcoin.com.

The USA CBD Expo Chicago aims to be the greatest and largest CBD/hemp event in the country, bringing the most creative and best goods and brands to businesses and consumers on a constant basis, and compressing a rapidly growing industry into one all-encompassing, top event. This event is geared toward both newbies to the CBD sector and seasoned veterans. The conference will feature some of the industry’s top experts, who will deliver a variety of instructional seminars, keynote talks, and workshops to attendees. The seminars will focus on the commercial side of the CBD and hemp industries, as well as current and future CBD market trends, health advantages, ongoing legalization initiatives, and medicinal use cases. CBD for sexual wellbeing, psychedelics education, the potency of medicinal mushroom extracts, and information about delta-8 and its legality are among the topics to be discussed. Why Attend the Expo? The windy city has a population of about 10 million people and receives over 58 million visitors each year. Many of them are attracted by the recent legalization of recreational cannabis, which has seen monthly retail sales of the substance surge to an estimated $40 million in income. You have an opportunity to attend the expo and educate yourself on the various aspects of the cannabis industry and how you could step in it. Seminars educating people on the various resources and methodologies about the wonder plant can help you as well! Key Convention Aspects:

• The USA CBD Expo, which is part of the country’s largest CBD event series, will cater to CBD industry novices as well as seasoned industry professionals.
• A series of keynote presentations and conversations will be offered by some of the industry’s greatest thinkers and innovators during the conference.
• The Expo will include over 500 of the industry’s largest and most innovative brands, all of which will present their different product lines under one roof.

The USA CBD Expo will feature a wide range of industry thought leaders, including Angela Ardolino of CBD Dog Health, Asa Waldstein of the Supplement Advisory Group, Angela Boyce of Primo Gardens, Jody McGinness of the Hemp Industries Association, and Jason Gann, star of Wilfred and representing Wilfred CBD, among a variety of other featured speakers. To know more about this event, visit https://usacbdexpo.com/chicago/.

• License prequalification should give HENC shareholders great confidence in strategic Michigan business plan
• Hero Technologies, Blackbox now beginning the last step in process of obtaining licensing approval
• Once full funding has been reached, BlackBox anticipates being shovel ready within two months

In its ongoing commitment to position itself as a multistate operator in the cannabis sector, Hero Technologies (OTC: HENC) is focused on becoming fully licensed in Michigan. As part of that process, the company recently announced that Blackbox Systems and Technologies LLC, a HENC subsidiary, has fulfilled the requirements for step 1 prequalification approval for a Class C Medicinal Use cannabis license in Michigan; Blackbox also received step 1 prequalification approval for a Class C Adult-Use cannabis license (https://ibn.fm/x5UjK). “Michigan’s two-step marijuana licensing process is one of the toughest in the country, and passing the scrutiny of state regulators for license prequalification should give our shareholders great confidence in our Michigan business plan,” said Hero Technologies CEO Gina Serkasevich. “The state of Michigan is also one of the fastest-growing cannabis markets in the nation, with monthly sales approaching $150 million in only the second year of legal operations, so our shareholders should also be excited about our near-term prospects for rapid growth.” In order to obtain step 1 prequalification approval, companies must provide detailed information to the Michigan Marijuana Regulatory Agency (“MRA”) regarding sources of capitalization, corporate officers, directors, major shareholders, insurance compliance, and financial statements attested to by a certified public accountant; submitting companies and key officials must also undergo extensive background checks. HENC went to great lengths to meet the requirements and provide all the information required in order to obtain the prequalification approvals for both licenses. With those approvals in hand, Hero Technologies and Blackbox are now beginning the next — and last — step in the process of obtaining licensing approval in Michigan: establishment use or full license approval for a newly constructed medical marijuana facility. Completion of this second step will allow HENC to move forward with its plans for cultivation of cannabis in Michigan. Looking ahead, the company has already obtained approval from the township of Pulaski for three class C medicinal use cannabis licenses dependent on completion of step 2 and MRA approval. That approval came after HENC provided Pulaski officials with detailed information regarding the proposed facility site as well as construction documents, a business plan, security arrangements, a sanitation plan and revenue projections. The company has noted that final approval and licensing for both medicinal and adult-use licenses will come after the greenhouse have been completed, including obtaining a certificate of occupancy and the final MRA inspection. With costs for the Michigan project estimated to reach $8.94 million, the company is working to raise the funds. Once full funding has been reached, BlackBox anticipates being shovel ready within two months. In addition to its Michigan expansion plans, Hero Technologies is undertaking expansion in Colorado through its wholly owned subsidiary Mile High Green LLC. The company’s strategic business plan includes cannabis genetic engineering, space for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. HENC is also planning to expand in Massachusetts through its wholly owned subsidiary MassCannabis LLC. In addition, Hero Technologies owns and operates two hemp websites: HighlyRelaxing.com under Highly Relaxing LLC and VeteranHempCo.com. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Avricore, through its HealthTab(TM) flagship offering, is bringing health diagnosis and treatment closer to people
• The point-of-care testing market, which Avricore is part of, shows incredible potential for growth in the coming years
• Strategic investments and critical partnerships with other key players in the industry have allowed Avricore to stand out among its competitors
• This has also enabled the company to create value for stakeholders and better outcomes for patients

The point-of-care testing market is projected to be valued at $50.6 billion by 2025, up from $29.5 billion in 2020. This will represent a compounded annual growth rate (“CAGR”) of 11.4% during the forecast period, mainly fueled by the rising cases of infectious diseases, technological advancements of point-of-care devices, along with an increase in investments by key companies and players in the industry (https://ibn.fm/qn479). One such player is Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a company at the forefront of moving pharmacy forward. Described as a heath diagnostics technology innovator focused on acquiring and developing early-stage technologies, Avricore has been at the frontage of offering a turnkey point-of-care testing platform that, so far, has created value for stakeholders and better outcomes for its patients. Through HealthTab(TM), Avricore’s flagship offering, the company has effectively turned pharmacies into community diagnostic centers, bringing health diagnosis and treatment even closer to the people. With this platform, pharmacies take on a more significant role in primary health services, ultimately improving the quality of life for patients living with chronic illnesses. Avricore understands that partnering with pharmacies is ideal if at all the point-of-care model is to work effectively. In the United States (“U.S.”), the United Kingdom (“U.K.”), and Canada, there are over 110,000 pharmacy locations. Each of them can be equipped with Avricore’s three rapid testing devices, allowing patients to easily and quickly diagnose anything from their kidney functions to Covid-19 (https://ibn.fm/9yf4S). For instance, in North America alone, it is projected that over 102 million people will be dealing with diabetes or prediabetes by 2030. Having point-of-care facilities close by, mainly in their closest pharmacies, will allow them to quickly diagnose their conditions and manage them properly before it is too late. Having partnered with other key industry players such as Abbott Rapid Diagnostics and Shoppers Drug Mart, Avricore has secured the integral equipment necessary for patient point-of-care testing and locations that bring the equipment even closer to the target patients. By doing so, it is, ultimately, driving better outcomes for them. Additionally, it has brought on board companies that believe in the future of point-of-care testing and share in Avricore’s vision. “We’re proud to be part of this amazing journey with HealthTab as we believe point-of-care testing in pharmacies is the future,” noted Daniel Saint-Pierre, the General manager of Abbott Rapid Diagnostics. Mohammed Adel Elsabakhawi, a Pharmacist and Associate Owner of Shoppers Drug Mart, also noted, “I’m so excited to have HealthTab in my store because I believe it demonstrates a new and better way to do pharmacy practice.” Avricore has three main testing instruments- Afinion 2(TM), I-Stat, and ID Now. Afinion 2 is beneficial for heart disease screening and diabetes diagnosis, while I-Stat tests kidney function and electrolytes. ID Now, Avricore’s most recent addition, is used to test Influenza A and B, Strep and Covid-19. So far, the company has tested and developed its technology and is in the commercialization stage, intending to expand into more pharmacies in Canada and around the world (https://ibn.fm/6LRbL). Avricore’s ultimate goal is to become the leading provider of point-of-care testing in pharmacy and real-world evidence studies, and its achievements so far place it on track to achieving this goal. The company projects that by October 2023, it will have its instruments in about 600 different locations, with estimated revenues surpassing $800,000. It also projects that Canada will play host to the majority of the pharmacies, followed by the U.S. and the U.K. With its revenue model broken into equipment leasing, consumables, screening tests, data, and API integration, Avricore demonstrates its commitment to offering value-added patient services and creating value to its shareholders. Even with the success achieved so far, the company is still pushing the envelope, innovating with its technology and forging healthy relationships that allow it to move even closer to achieving this specific goal. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• The company recently announced the beta launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores
• US diabetes-related healthcare expenditures totalled $760 billion in 2019 alone, equating to an annual spend of over $9,000 per diabetic patient

Nemaura Medical (NASDAQ: NMRD) is a cutting-edge medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company recently carried out the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI based mobile application (https://ibn.fm/FsV8g). MiBoKo, an addition to Nemaura Medical’s diabetes-focused product portfolio, has been in development for the past 18 months and seeks to address a significant and growing mass-market opportunity which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores based on glucose tolerance or insulin resistance. Prediabetic patients or those facing obesity concerns or looking to monitor their glucose intake would benefit from using the application. Nemaura Medical’s cutting-edge health tracking program uses a wearable sensor and mobile app that provides users with personalized information by tracking their metabolism when used in conjunction with one another. For example, users can draw insights into how their bodies process sugar by tracking their metabolic health score. This figure provides a holistic overview of the impact of an individual’s daily nutrition on their health. Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer, commented in regard to MiBoKo’s launch, “A person’s response to sugar intake can influence a number of factors from appetite and body weight to sleep patterns, energy levels, and even mood, not to mention also being a considerable factor in chronic diseases like diabetes, heart disease, and dementia.” Chowdhury continued, “With MiBoKo, we are able to extend our proprietary non-invasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health.” In addition to receiving real-time updates on their metabolic health scores, MiBoKo users will be eligible to receive weekly and monthly reports illustrating the changes in their metabolic health scores as well as providing a breakdown of how individual habits were impacting their overall health and wellbeing. The MiBoKo application will also suggest how to amend daily routines (i.e., eating more or less of a particular food or exercising during peak energy levels), providing MiBoKo users with granular and actionable intelligence on how to transform their health for the better. Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. Through their flagship product, the sugarBEAT(R), a wearable and non-invasive continuous glucose monitor, and now, the MiBoKo application, Nemaura Medical have sought to improve the health prospects for an ever-increasing proportion of the global population, with US diabetes-related health care expenditures totalling over $760 billion in 2019 alone (https://ibn.fm/88DpX). For more information, visit the company’s websites at www.NemauraMedical.com or www.MiBoKo.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Infobird, a leading software-as-a-service (SaaS) provider of AI powered customer engagement solutions in China, is one of the few companies in China that has built a customer engagement SaaS on a cloud-native architecture, and has remained consistent with innovation and offering unique customer engagement solutions
• The company’s products and services ride on the backbone of their self-developed, cloud-computing structure, robotic-process-automation (“RPA”) machine learning, patented Voice over Internet Protocol (“VoIP”), no-code development platform, and other powerful technologies.
• Infobird is also pioneering a new product that is differentiated from standard private domain traffic tools, allowing enterprises with a large customer base to cost-effectively personalize and automate their services

Infobird (NASDAQ: IFBD) has consistently innovated and offered unique customer-engagement solutions. The company has made a name for itself by leveraging proprietary next-generation technology, a product of years of research and development (“R&D”). This has allowed it to stamp its position as a leader in the Software-as-a-Service (“SaaS”) industry, particularly in the Chinese market. Infobird has been known to help companies manage the complete customer journey, starting from pre-sales activities to post-sale customer support. All this has ridden on the backbone of a self-developed, cloud-computing structure, robotic-process-automation (“RPA”) machine learning, patented Voice over Internet Protocol (“VoIP”), no-code development platform and many other such technologies (https://ibn.fm/uF6Th). Incremental improvements and developments over the years have rendered Infobird a pioneer in the industry and a trailblazer in what its technology can do from a customer relationship management (“CRM”) standpoint. Infobird is one of the very few companies in China to have built, from scratch, a customer engagement SaaS on a cloud-native architecture. A resource-intensive project in its development translates to cost-savings for clients who can scale their operations affordably and effectively without sacrificing on security or stability. This, in addition to Infobird’s no-code development, place it in a league of its own while also offering it an opportunity to further develop new SaaS with pre-programmed microservices at a significantly low cost and with quick reactions to new market opportunities. It is projected that the CRM market will be valued at $96.39 billion by 2027, up from $41.93 billion in 2019. Infobird plans to capitalize on this growth and play a central role in the industry’s growth. Recent client acquisitions such as SaSa, a Hong Kong beauty retailer, Zu Li Jian, a leading footwear brand in China, and a top fintech enterprise in China are all strong indications of a company positioning itself for the growth to come. Infobird is also pioneering a new product that is differentiated from standard private domain traffic tools. It is achieving this through the integration of RPA analysis and Artificial Intelligence (“AI”), thereby allowing enterprises with a large customer base to personalize and automate their services while reducing their operational costs and improving efficiency. Infobird’s customer-engagement solutions are unlike any other in the market today. The company is constantly pushing the envelope with innovation and technology, further reinforcing its title as a company of firsts and also as the undisputed industry leader. For more information, visit the company’s website at www.Infobird.com/en/index. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• FingerMotion’s focus has been on Sapientus, a major milestone for the company; delivering data-enabled insurance solutions that employ behavioral insights to change the existing service options
• Sapientus uses algorithms that supply insurers with actionable intel and facilitate efficient and effective delivery while increasing the ability to calculate risk and create more innovative products
• The company’s Nasdaq application has been submitted; FingerMotion has brought in third-party advisors to assist legal counsel in responding in a timely manner to any examiner questions
• SEC filings show that FingerMotion has allocated research and development funding to rich communications services, and it is expected that the company will be tapping into that industry’s growth potential

In a recent corporate update call (https://ibn.fm/BHbi7), tech company FingerMotion (OTCQX: FNGR) has shown increasing trends, especially in reports filed with the SEC. As an evolving technological company with core competencies in SMS/MMS services, mobile payment and recharge solutions, and big data insights, these trends support the company’s increasing focus on research and development, bolstering the commitment to developing high-demand applications for both consumers and businesses. Most of FingerMotion’s expenditures during 2021 have been a result of its youngest operational division, Sapientus. Sapientus represents a major milestone for the company. The division allows for the delivery of data-enabled insurance solutions employing behavioral insights to augment existing service options. The service offerings increase the insurers’ ability to calculate risk and create more innovative products. Sapientus uses advanced algorithms that supply more actionable intel and facilitate efficient and effective delivery. All available data is integrated to create proprietary risk matrices, which are then used in the final product offering. Sapientus has generated $33,077 in revenue during Q4 2021 and $98,715 in Q1 2022, and the quarter-over-quarter increase clearly shows the division’s growing success (https://ibn.fm/9AHXL). “In the past few years, we’ve had our inhouse team of actuaries and data scientists, who really know the ins and outs of the insurance industry, and what they’ve been doing is they’ve been deciphering information from all these different sources and putting them in the risk metrics that could provide those fresh insights and intelligence for the insurance field,” CEO Martin Shen said in the August corporate update (https://ibn.fm/BgOPy). The company’s current Nasdaq application was also discussed in the corporate update. An initial application for the Nasdaq listing has been submitted, and the first examiner letter has been received. FingerMotion has since hired private advisors and, with the assistance of its legal counsel, responded quickly to the examiner’s initial letter. While the process is well on its way to potential approval, FingerMotion acknowledges there is still a substantial amount of ground to cover before approval is granted. The company is remaining optimistic but realistic in the endeavor. In the August update, Mr. Shen shared a three-stage development strategy for FingerMotion:

• Stage 1
  • Partner with reinsurers
  • Revenue Sources: fees-for-services
• Stage 2
  • Expand analytics and risk metrics
  • Revenue Sources: fees-for-services; commissions; profit shares
• Stage 3
  • Integrate partners’ business into FingerMotion’s ecosystem
  • Revenue Sources: fees-for-services; commissions; profit shares

FingerMotion’s additional focus is also on the research and development of rich communications services (“RCS”). RCS is an emerging technology that revolutionizes text-based messaging by eliminating constraints commonly associated with short text messaging. Extended capabilities of RCS include file sharing, video calling, group chat, and more native services without the use of third-party applications. As a market, RCS is expected to grow from $5.2 billion in 2020 to $11.7 billion by 2025, registering a CAGR of 17.6% during the forecast period (https://ibn.fm/aRbDm). Having already allocated research and development funding to this sector (per SEC filings), FingerMotion is poised to tap into this particular growth opportunity with a dedicated RCS division. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR